The Time Toxicity of Cancer Treatment

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness

The ESCAPE Investigators and ESCAPE Study Coordinators* (2005) · JAMA · doi:10.1001/jama.294.13.1625 · Cited by 1,544

Balanced Crystalloids versus Saline in Noncritically Ill Adults

Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., Slovis, C. M., Lindsell, C. J., Ehrenfeld, J. M., Siew, E. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711586 · Cited by 1,170

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Lamarca, Á., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S. J., Gillmore, R., Wadsley, J., Patel, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00027-9 · Cited by 781

NXY-059 for Acute Ischemic Stroke

Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660

Physical rehabilitation for older patients hospitalized for heart failure

Kitzman, D. W., Whellan, D. J., Duncan, P., Pastva, A. M., Mentz, R. J., Reeves, G. R., Nelson, M. B., Chen, H., Upadhya, B., Reed, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026141 · Cited by 594

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309

Days Spent at Home — A Patient-Centered Goal and Outcome

Groff, A. C., Colla, C. H., & Lee, T. H.-Y. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607206 · Cited by 272

Digital health and telehealth in cancer care: A scoping review of reviews

Shaffer, K. M., Turner, K. L., Siwik, C., Gonzalez, B. D., Upasani, R., Glazer, J. V., Ferguson, R. J., Joshua, C., & Low, C. A. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00049-3 · Cited by 263

Patient-Reported Outcome Measures in Cancer Care

Balitsky, A. K., Rayner, D. G., Britto, J., Lionel, A. C., Ginsberg, L., Cho, W., Wilfred, A. M., Sardar, H., Cantor, N., Mian, H. S., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.24793 · Cited by 134

Addressing Transportation Insecurity Among Patients With Cancer

Graboyes, E. M., Chaiyachati, K. H., Gall, J. S., Johnson, W., Krishnan, J. A., McManus, S. S., Thompson, L., Shulman, L. N., & Yabroff, K. R. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac134 · Cited by 102

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Garcia‐Manero, G., McCloskey, J. K., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Al‐Kali, A., Deeg, H. J., Patel, P. A., Sabloff, M., Keating, M., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00338-1 · Cited by 94

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

Gupta, A., O'Callaghan, C. J., Zhu, L., Jonker, D. J., Wong, R. P. W., Colwell, B., Moore, M. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00737 · Cited by 79

Patient, Caregiver, and Clinician Perspectives on the Time Burdens of Cancer Care

Gupta, A., Johnson, W. V., Henderson, N. L., Ogunleye, O. O., Sekar, P., George, M., Breininger, A., Kyle, M. A., Booth, C. M., Hanna, T. P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47649 · Cited by 72

The unequal burden of time toxicity

Johnson, W. V., Blaes, A. H., Booth, C. M., Ganguli, I., & Gupta, A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.01.006 · Cited by 61

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective

Mertz, S. A., Benjamin, C., Girvalaki, C., Cardone, A., Gono, P., May, S. G., Comerford, E., Than, K., Birch, K., Roach, M., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.07.006 · Cited by 56

The human crisis in cancer: a Lancet Oncology Commission

Rodin, G., Feldman, A., Trapani, D., Skelton, M., Unger‐Saldaña, K., Essue, B. M., Pihlak, R., Walshe, C., Rosa, W. E., Banegas, M. P., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00530-3 · Cited by 73

Treatment burden in individuals living with and beyond cancer: A systematic review of qualitative literature

Adam, R., Nair, R., Duncan, L., Yeoh, E., Chan, J., Vilenskaya, V., & Gallacher, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286308 · Cited by 56

Consuming Patients’ Days: Time Spent on Ambulatory Appointments by People With Cancer

Kagalwalla, S., Tsai, A. K., George, M., Waldock, A., Davis, S., Jewett, P. I., Vogel, R. I., Ganguli, I., Booth, C. M., Dusetzina, S. B., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae016 · Cited by 49

Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials

Gyawali, B., Eisenhauer, E. A., van der Graaf, W., Booth, C. M., Cherny, N. I., Goodman, A. M., Koven, R., Pe, M. L., Marini, B. L., Mohyuddin, G. R., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00451-0 · Cited by 50

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma

Bateni, S. B., Nguyen, P., Eskander, A. E., Seung, S. J., Mittmann, N., Jalink, M., Gupta, A., Chan, K., Hong, N. J. L., & Hanna, T. P. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.3179 · Cited by 48

Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial

Soto‐Pérez‐de‐Celis, E., Dale, W., Katheria, V., Kim, H., Fakih, M., Chung, V. M., Lim, D. W., Mortimer, J. E., Chien, L. C., Charles, K., et al. (2024) · Cancer · doi:10.1002/cncr.35333 · Cited by 46

Health Care Contact Days Among Older Adults in Traditional Medicare

Ganguli, I., Chant, E. D., Orav, E. J., Mehrotra, A., & Ritchie, C. S. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2331 · Cited by 44

Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit

Gupta, A., Brundage, M., Galica, J., Karim, S., Koven, R., Ng, T. L., O’Donnell, J., tenHove, J., Robinson, A. G., & Booth, C. M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae187 · Cited by 46

The intersecting time, administrative, and financial burdens of a cancer diagnosis

Parsons, H. M., Gupta, A., Jewett, P. I., & Vogel, R. I. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae252 · Cited by 46

Health Care Contact Days Experienced by Decedents With Advanced GI Cancer

Patel, V. R., Ramesh, V., Tsai, A. K., Sedhom, R., Westanmo, A. D., Blaes, A. H., Vogel, R. I., Parsons, H. M., Hanna, T. P., Ganguli, I., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00232 · Cited by 42

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Lübbert, M., Wijermans, P., Kiciński, M., Chantepie, S., van der Velden, W. J. F. M., Noppeney, R., Griškevičius, L., Neubauer, A., Crysandt, M. M., Vrḫovac, R., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00273-9 · Cited by 40

Time toxicity associated with early phase clinical trial participation

Nindra, U., Shivasabesan, G., Childs, S., Yoon, R., Haider, S., Hong, M., Cooper, A. J., Roohullah, A., Wilkinson, K., Pal, A., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102046 · Cited by 39

Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer

Hsu, M. L., Boulanger, M. C., Olson, S., Eaton, C. K., Prichett, L. M., Guo, M. Z., Miller, M. E., Brahmer, J. R., Forde, P. M., Marrone, K. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6872 · Cited by 39

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial

Gupta, A., Hay, A. E., Crump, M., Djurfeldt, M., Zhu, L., Cheung, M. C., Shepherd, L. E., Chen, B. E., & Booth, C. M. (2023) · The Oncologist · doi:10.1093/oncolo/oyad128 · Cited by 37

Rapid Advances in Resectable Non–Small Cell Lung Cancer

West, H., & Kim, J. Y. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5276 · Cited by 37

Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma

Banerjee, R. K., Cowan, A. J., Chavez-Ortega, M., Missimer, C., Carpenter, P. A., Ueda, M., Salit, R. B., Vo, P., Lee, C. J., Mehta, R. S., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.013 · Cited by 37

Arf1 Ablation in Colorectal Cancer Cells Activates a Super Signal Complex in DC to Enhance Anti‐Tumor Immunity

Ma, H., Fang, W., Li, Q., Wang, Y., & Hou, X. S. (2023) · Advanced Science · doi:10.1002/advs.202305089 · Cited by 35

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

Meyers, D. E., Pasternak, M., Dolter, S., Grosjean, H. A. I., Lim, C. A.-R., Stukalin, I., Goutam, S., Navani, V., Heng, D. Y. C., Cheung, W. Y., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100482 · Cited by 35

Tackling Non–Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes

Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40

Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues

Maspero, M., Sposito, C., Virdis, M., Citterio, D., Pietrantonio, F., Bhoori, S., Belli, F., & Mazzaferro, V. (2023) · Cancers · doi:10.3390/cancers15020345 · Cited by 35

Cancer diagnosis and treatment in working‐age adults: Implications for employment, health insurance coverage, and financial hardship in the United States

Yabroff, K. R., Doran, J. F., Zhao, J., Chino, F. L., Shih, Y. T., Han, X., Zheng, Z., Bradley, C. J., & Bryant, M. F. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21837 · Cited by 34

Logistic burdens of cancer care: A qualitative study

Dona, A. C., Jewett, P. I., Hwee, S., Brown, K. A., Solomon, M., Gupta, A., Teoh, D. G. K., Yang, G., Wolfson, J. A., Fan, Y., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300852 · Cited by 34

Trajectories of Health Care Contact Days for Patients With Stage IV Non–Small Cell Lung Cancer

Gupta, A., Nguyen, P., Kain, D., Robinson, A. G., Kulkarni, A. A., Johnson, D. H., Presley, C. J., Blaes, A. H., Rocque, G. B., Ganguli, I., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.4278 · Cited by 34

Exercise as cancer treatment: A clinical oncology framework for exercise oncology research

Courneya, K. S., & Booth, C. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.957135 · Cited by 33

Health Care Contact Days Among Older Cancer Survivors

Gupta, A., Chant, E. D., Mohile, S. G., Vogel, R. I., Parsons, H. M., Blaes, A. H., Booth, C. M., Rocque, G. B., Dusetzina, S. B., & Ganguli, I. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00590 · Cited by 30

Trajectory of Healthcare Contact Days for Veterans With Advanced Gastrointestinal Malignancy

Johnson, W. V., Phung, Q. H., Patel, V. R., Tsai, A. K., Arora, N., Klein, M. A., Westanmo, A. D., Blaes, A. H., & Gupta, A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad313 · Cited by 28

Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants

Durbin, S., Lundquist, D., Pelletier, A. J., Jimenez, R., Petrillo, L. A., Kim, J. S., Lynch, K., Healy, M. E., Johnson, A., Ollila, N., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00811 · Cited by 27

A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?

Cherny, N. I., Nortjé, N., Kelly, R., Zimmermann, C., Jordan, K., Kreye, G., Le, N., & Adelson, K. B. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104099 · Cited by 30

Time toxicity in cancer care: A concept analysis using Walker and Avant's method

Nwozichi, C. U., Salako, O., Ojewale, M. O., Faremi, F. A., Brotobor, D., Olaogun, E. T., Oshodi‐Bakare, M., & Martins‐Akinlose, O. D. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100610 · Cited by 26

Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential

Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz‐Banecka, J., & Hellmann, A. (2024) · Molecules · doi:10.3390/molecules29174280 · Cited by 29

Efficacy‐effectiveness gaps in oncology: Looking beyond survival

Wilson, B. E., Hanna, T. P., & Booth, C. M. (2023) · Cancer · doi:10.1002/cncr.35075 · Cited by 25

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Hong, S., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J. C., Bergstrom, C. P., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06718-6 · Cited by 26

Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care

Schuler, T., Roderick, S., Wong, S., Kejda, A., Grimberg, K., Lowe, T., Kipritidis, J., Back, M., Bergamin, S., Carroll, S. L., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.09.041 · Cited by 24

Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study

Paggio, J. C. D., Naipaul, R., Gavura, S., Mercer, R. E., Koven, R., Gyawali, B., Wilson, B. E., & Booth, C. M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00072-x · Cited by 24

“It is not the fault of the health care team - it is the way the system works”: a mixed-methods quality improvement study of patients with advanced cancer and family members reveals challenges navigating a fragmented healthcare system and the administrative and financial burdens of care

Dillon, E. C., Martinez, M. C., Li, M., Mann-Grewal, A. K., Luft, H. S., Liang, S., Colocci, N., Lai, S., & Patel, M. I. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11744-z · Cited by 23

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study

Geissler, K. H., Kořı́stek, Z., Bernal, T., Novák, J., Rodríguez‐Macías, G., Metzelder, S., Illés, Á., Mayer, J., Arnán, M., Keating, M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19741 · Cited by 23

Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung Cancer in Routine Clinical Practice: A Nationwide Cohort Study

Ording, A. G., Skjøth, F., Poulsen, L. Ø., Szejniuk, W. M., Jakobsen, E. H., Christensen, T. D., Noble, S., & Overvad, T. F. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00526 · Cited by 22

Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction

Pinter, M., Fulgenzi, C. A. M., Pinato, D. J., & Scheiner, B. (2025) · Gut · doi:10.1136/gutjnl-2025-334928 · Cited by 23

Climate toxicity: An increasingly relevant clinical issue in Cancer Care

Weadick, C., Keogh, R. J., Carroll, H. K., Boldrin, S., Mulroe, E., Murphy, L., Sheils, B., Barry, A. S., & O’Reilly, S. (2023) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2023.100410 · Cited by 20

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Thota, R., Hurley, P. A., Miller, T. M., Bruinooge, S. S., Lipset, C. H., Harvey, R. D., Black, L. J., Dinsdale, A., Merrill, J. K., Pollastro, T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00961 · Cited by 20

Common Sense Oncology: Equity, Value, and Outcomes That Matter

Wilson, B. E., Sengar, M., Tregear, M., van der Graaf, W. T. A., Battisti, N. M. L., Csaba, D. L., Soto‐Pérez‐de‐Celis, E., Gyawali, B., & Booth, C. M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100039 · Cited by 20

A Life-Affirming Palliative Care Model for Severe and Enduring Anorexia Nervosa

Treem, J., Yager, J., & Gaudiani, J. L. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.703 · Cited by 18

Mitigating time toxicity in lymphoma and multiple myeloma

Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 18

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

Waks, A. G., Chen, E., Graham, N., Frey, A., Almeida, K., Attaya, V., Ryding, C., Abbass, I. M., Fung, A., Sussell, J. A., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00021 · Cited by 17

Time toxicity among older patients with cancer treated with palliative systemic therapy

Baltussen, J. C., Cárdenas-Reyes, P., Chávarri-Guerra, Y., Ramírez-Fontes, A., Morales-Alfaro, A., Portielje, J. E. A., Ramos-López, W. A., Rosado-Canto, V., & Soto‐Pérez‐de‐Celis, E. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08844-1 · Cited by 17

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia

Roboz, G. J., Zeidan, A. M., Mannis, G. N., Montesinos, P., Arnán, M., Savona, M. R., Odenike, O. M., McCloskey, J. K., Amin, H., Fathi, A. T., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2510223 · Cited by 16

Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis

Prasad, V. K., Olivier, T., Chen, E. Y.-S., & Haslam, A. (2022) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2022.100363 · Cited by 16

Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers

Agrawal, N. Y., Thawani, R., Edmondson, C. P., & Chen, E. Y.-S. (2023) · Cancers · doi:10.3390/cancers15235677 · Cited by 17

Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

Stevens, S. X., Nindra, U., Shahnam, A., Wei, J., Bray, V., Pal, A., Yip, P. Y., Linton, A., Blinman, P. L., Nagrial, A. M., et al. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101705 · Cited by 16

Reporting time toxicity in prospective cancer clinical trials: A scoping review

Quinn, P. L., Saiyed, S., Hannon, C., Sarna, A., Waterman, B. L., Cloyd, J. M., Spriggs, R., Rush, L. J., McAlearney, A. S., & Ejaz, A. M. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08487-2 · Cited by 15

The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17

Gupta, A., O'Callaghan, C. J., Zhu, L., Jonker, D. J., Wong, R. P. W., Colwell, B., Moore, M. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae077 · Cited by 16

Treatment burden in survivors of prostate and colorectal cancers: a qualitative interview study

Adam, R., Duncan, L., MacLennan, S. J., & Locock, L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068997 · Cited by 15

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1

Miyajima, Y., & Kawakami, T. (2025) · Cancers · doi:10.3390/cancers17071120 · Cited by 15

Novel patient-centred outcome in cancer care, days at home: a scoping review protocol

Ribeiro, T., Mahar, A. L., Jerath, A., Bondzi‐Simpson, A., Barabash, V., Barr, A. A., Wright, F. C., Kosyachkova, E., Deleemans, J. M., Coburn, N. G., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071201 · Cited by 14

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

Tannock, I. F., Bouche, G., Goldstein, D. A., Goto, Y., Lichter, A. S., Prabhash, K., Ranganathan, P., Saltz, L. B., Sonke, G. S., Strohbehn, G. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.006 · Cited by 15

Elucidating the Benefit of Radiation Therapy in GI Cancers: Rethinking Trial End Points and Patient Selection

Sanford, N. N., Hong, T. S., & Hall, W. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01402 · Cited by 14

Are We Ready for Life in the Fast Lane? A Critical Review of Preoperative Hypofractionated Radiotherapy for Localized Soft Tissue Sarcoma

Guadagnolo, B. A., & Baldini, E. H. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.12.003 · Cited by 14

Home Time Among Older Adults With Acute Myeloid Leukemia Following Chemotherapy

Richardson, D. R., Zhou, X., Reeder-Hayes, K. E., Jensen, C. E., Islam, J. Y., Loh, K. P., Gupta, A., Basch, E., Bennett, A. V., Bridges, J. F. P., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1823 · Cited by 14

Time Burdens for Participants With Advanced Cancer in Phase I Trials: A Cross-Sectional Study

Iskander, R., Robart, A. M., Moyer, H., Nipp, R. D., Gupta, A., & Kimmelman, J. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00334 · Cited by 14

A Fifth of Their Days: The Time Commitments of Advanced Cancer and Its Care

Johnson, W. V., Hsu, M. L., & Gupta, A. (2025) · JCO Oncology Practice · doi:10.1200/op-24-01085 · Cited by 14

Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative

Narita, Y., Mizuno, T., Suda, T., Kurono, J., Ishizuka, Y., Iida, Y., Kondo, A., Shimomura, K., Yamada, C., Hotta, E., et al. (2025) · Cancers · doi:10.3390/cancers17121996 · Cited by 13

Health Care Contact Days and Outcomes in Clinical Trials vs Routine Care Among Patients With Non–Small Cell Lung Cancer

Gupta, A., Nguyen, P. L., Wilson, B. E., Booth, C. M., & Hanna, T. P. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.5033 · Cited by 13

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Russler‐Germain, D. A., & Ghobadi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168622 · Cited by 13

Metronomic chemotherapy in ovarian cancer

Garg, V., & Kumar, L. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216469 · Cited by 12

Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Zeidan, A. M., Perepezko, K. M., Salimi, T., Washington, T. L., & Epstein, R. S. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241257313 · Cited by 12

Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials

Gupta, A., Till, C., Vaidya, R., Hershman, D. L., & Unger, J. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0778 · Cited by 12

New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment – An oncogeriatric perspective

Diekmann, B., Timmerman, M., Hempenius, L., van Roon, E., Franken, B., & Hoogendoorn, M. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101631 · Cited by 12

Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy

Etteldorf, A., Rotolo, S. M., Sedhom, R., Vogel, R. I., Blaes, A. H., Dusetzina, S. B., Virnig, B. A., & Gupta, A. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00051 · Cited by 12

Antibiotic prophylaxis in immunosuppressed patients – Missed opportunities from trimethoprim-sulfamethoxazole allergy label

Lee, W., Lam, L., Bacchi, S., Jiang, M., Inglis, J. M., Smith, W., & Hissaria, P. (2024) · World Allergy Organization Journal · doi:10.1016/j.waojou.2023.100856 · Cited by 12

“The biggest challenge is there’s never a routine”: a qualitative study of the time burdens of cancer care at home

Sekar, P., Johnson, W. V., George, M., Breininger, A., Parsons, H. M., Vogel, R. I., Blaes, A. H., & Gupta, A. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-024-09132-8 · Cited by 11

Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens

Cronin, C., O'Sullivan, A., & Naidoo, J. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6809 · Cited by 11

Perceived Appropriateness of Assessing for Health-related Socioeconomic Risks Among Adult Patients with Cancer

Vu, M., Boyd, K., Marchis, E. H. D., Garnache, B. G., Gottlieb, L. M., Gross, C. P., Lee, N. K., Lindau, S. T., Mun, S., Winslow, V. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0283 · Cited by 12

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Gelderblom, H. A. J., Jones, R. L., Blay, J., George, S., von Mehren, M., Zalcberg, J. R., Kang, Y., Razak, A. A., Trent, J. C., Attia, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113245 · Cited by 11

The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up

Etteldorf, A., Sedhom, R., Rotolo, S. M., Vogel, R. I., Booth, C. M., Blaes, A. H., Virnig, B. A., Dusetzina, S. B., & Gupta, A. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07472-x · Cited by 11

Characterization of time toxicity in older patients with metastatic breast cancer

Atre, S. Y., Soulos, P. R., Kuderer, N. M., Gross, C. P., Baum, L. V. M., Dinan, M. A., & Lustberg, M. B. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07379-7 · Cited by 10

Telehealth and Health Care Contact Days Among Patients With Advanced Cancer After COVID-19

Duffens, A. M., Zhu, S., Shirazi, A., Gupta, A., & Liu, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16762 · Cited by 10

The impact of travel time to cancer treatment centre on post-diagnosis care and mortality among cancer patients in Scotland

Turner, M. E., Carriere, R., Fielding, S., Ramsay, G., Samuel, L. M., Maclaren, A. S., & Murchie, P. (2023) · Health & Place · doi:10.1016/j.healthplace.2023.103139 · Cited by 10

Is aggressive treatment of smoldering myeloma the path to curing myeloma?

Chakraborty, R., Hadidi, S. A., Cliff, E. R. S., & Mohyuddin, G. R. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009658 · Cited by 10

Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants – a pilot, institutional experience

Zhang, S., Patel, K. R., Dusenbery, K., Alshreef, A., Sterling, D., Sloan, L., Reynolds, M. A., Chen, C. C., & Ferreira, C. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04631-4 · Cited by 9

Transforming patient-centered cancer care using telehealth: the MATCHES Center

Bange, E. M., Daly, R. M., Lipitz‐Snyderman, A., Kuperman, G. J., Polubriaginof, F. C. G., Liebertz, C., Doshi, S. D., Stevanović, K., Chan, K., Bernal, C., et al. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae004 · Cited by 9

A digital, decentralized trial of exercise therapy in patients with cancer

Underwood, W. P., Michalski, M., Lee, C. P., Fickera, G. A., Chun, S. S., Eng, S. E., Liu, L., Tsai, B. L., Moskowitz, C. S., Lavery, J. A., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01288-1 · Cited by 9

Health Care Contact Days in Older Adults With Metastatic Cancer

Gupta, A., Jazowski, S. A., Vaidya, A. U., Dusetzina, S. B., & Ganguli, I. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.47924 · Cited by 9

Diversity in Cancer Care

Akimoto, K. S., Taparra, K., Brown, T. P., & Patel, M. I. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000675 · Cited by 9

Telemedicine and Cancer Clinical Research

von Itzstein, M. S., Gwin, M. E., Gupta, A., & Gerber, D. E. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000695 · Cited by 9

Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review

Pichardo, M. S., Sanft, T. B., Ferrucci, L. M., Romero-Ramos, Y. M., Cartmel, B., Harrigan, M., Velázquez, A. I., Fayanju, O. M., Winer, E. P., & Irwin, M. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1079293 · Cited by 9

Management of malignant bowel obstruction

Gupta, A. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00333-3 · Cited by 9

The Patient's perspective: A review of the results from a radiotherapy patient experience survey in the North-West of England.

Hutton, D., Booker, P., Shuttleworth, S., Hall, T., Cain, M., Murphy, T., Woods, L., & Saunders, D. (2023) · Radiography · doi:10.1016/j.radi.2023.02.019 · Cited by 9

Racial differences in treatment adherence and response to acupuncture and cognitive behavioral therapy for insomnia among Black and White cancer survivors

Liou, K. T., Garland, S. N., Meghani, S. H., Kaye, N. M., Thompson, E., Li, Q. S., & Mao, J. J. J. (2024) · Cancer Medicine · doi:10.1002/cam4.7344 · Cited by 7

Feasibility, acceptability, and preliminary efficacy of a self-directed online psychosocial intervention for women with metastatic breast cancer: Finding My Way-Advanced

Rigg, A., Kemp, E., Koczwara, B., Butow, P. N., Girgis, A., Hulbert-Williams, N., Kaambwa, B., Long, R., Schofield, P. E., Turner, J., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08924-2 · Cited by 8

“The Cancer is My Life”: patient and caregiver perceptions of the time toxicity of palliative systemic cancer treatments for advanced gastrointestinal cancers

Stevens, S. X., El-Katateny, E., Lourenço, R. D. A., Booth, C. M., Shaw, J., & Vardy, J. L. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09621-4 · Cited by 8

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study

Alexander, M., Cheng, Y., Lee, S.-H., Passaro, A., Spira, A. I., Cho, B. C., Lim, S. M., Ohe, Y., Nagrial, A. M., Tan, J. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115624 · Cited by 9

Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence

Zeidan, A. M., Zhao, R., Epstein, R. S., & Salimi, T. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2544859 · Cited by 8

The Toxicity of Time

Daily, K. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7907 · Cited by 19

Time Toxicity of Cancer Care—A Call to Action

Doshi, S. D., Rappaport, J. A., & Bange, E. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.47930 · Cited by 8

Time Is Money, but for Whom? The Commodification of Time Toxicity in Oncology

Gupta, A., Patel, V. R., Sedhom, R., & Booth, C. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01458

‘Time Toxicity’ in the Metastatic Setting

DiGirolamo, E. (2026) · Oncology Times · doi:10.1097/01.cot.0000000000000380

Love in the Time of Cancer

Einhorn, L. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9755 · Cited by 1